JP2019518733A5 - - Google Patents

Download PDF

Info

Publication number
JP2019518733A5
JP2019518733A5 JP2018558750A JP2018558750A JP2019518733A5 JP 2019518733 A5 JP2019518733 A5 JP 2019518733A5 JP 2018558750 A JP2018558750 A JP 2018558750A JP 2018558750 A JP2018558750 A JP 2018558750A JP 2019518733 A5 JP2019518733 A5 JP 2019518733A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
glycopeptide antibiotic
composition according
sulfobutyl ether
beta cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018558750A
Other languages
English (en)
Japanese (ja)
Other versions
JP6946343B2 (ja
JP2019518733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/060653 external-priority patent/WO2017194385A1/en
Publication of JP2019518733A publication Critical patent/JP2019518733A/ja
Publication of JP2019518733A5 publication Critical patent/JP2019518733A5/ja
Application granted granted Critical
Publication of JP6946343B2 publication Critical patent/JP6946343B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018558750A 2016-05-09 2017-05-04 安定化されたグリコペプチド抗生物質製剤 Active JP6946343B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333357P 2016-05-09 2016-05-09
US62/333,357 2016-05-09
PCT/EP2017/060653 WO2017194385A1 (en) 2016-05-09 2017-05-04 Stabilized glycopeptide antibiotic formulations

Publications (3)

Publication Number Publication Date
JP2019518733A JP2019518733A (ja) 2019-07-04
JP2019518733A5 true JP2019518733A5 (enExample) 2020-06-18
JP6946343B2 JP6946343B2 (ja) 2021-10-06

Family

ID=58745200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018558750A Active JP6946343B2 (ja) 2016-05-09 2017-05-04 安定化されたグリコペプチド抗生物質製剤

Country Status (20)

Country Link
US (1) US10729708B2 (enExample)
EP (1) EP3454883A1 (enExample)
JP (1) JP6946343B2 (enExample)
KR (1) KR20190005940A (enExample)
CN (1) CN109069580A (enExample)
AR (1) AR109454A1 (enExample)
AU (1) AU2017262943B2 (enExample)
BR (1) BR112018072948A2 (enExample)
CA (1) CA3021935A1 (enExample)
CL (1) CL2018003147A1 (enExample)
CO (1) CO2018011701A2 (enExample)
EA (1) EA201892413A1 (enExample)
IL (1) IL262796A (enExample)
JO (2) JOP20170111B1 (enExample)
MX (1) MX388732B (enExample)
SA (1) SA518400392B1 (enExample)
SG (1) SG11201809908TA (enExample)
TW (2) TWI769694B (enExample)
UY (1) UY37233A (enExample)
WO (1) WO2017194385A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3542812T1 (sl) 2014-11-06 2021-04-30 Xellia Pharmaceuticals Aps Glikopeptidni sestavki
WO2021231361A1 (en) * 2020-05-11 2021-11-18 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing active metabolites of remdesivir for inhalation
US20230302032A1 (en) * 2020-08-04 2023-09-28 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
CN115804832A (zh) * 2021-09-14 2023-03-17 海南普利制药股份有限公司 一种万古霉素水溶液组合物
JPWO2023171588A1 (enExample) * 2022-03-08 2023-09-14
US20250295727A1 (en) * 2022-04-26 2025-09-25 Hikma Pharmaceuticals Usa Inc. Stable, ready-to-administer aqueous formulations of dalbavancin
GB202207345D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
GB202207344D0 (en) 2022-05-19 2022-07-06 Arecor Ltd Novel composition
CN117618338A (zh) * 2022-08-16 2024-03-01 海南普利制药股份有限公司 一种稳定的奥利万星药物水溶液及其制备方法
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
EP4601615A1 (en) * 2022-10-12 2025-08-20 Hikma Pharmaceuticals USA Inc. Liquid dalbavancin composition
EP4431083A1 (en) * 2023-03-16 2024-09-18 Adalvo Limited Formulation of dalbavancin
WO2025158262A1 (en) * 2024-01-23 2025-07-31 Lupin Limited Stable pharmaceutical compositions of dalbavancin as ready-to-dilute formulation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1278549A (en) * 1916-12-16 1918-09-10 J E Simmons Nut and bolt lock.
US4670258A (en) 1984-02-10 1987-06-02 Vanderbilt University Storable prepackaged aqueous solutions of vancomycin
US4885275A (en) 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
WO1997019690A1 (en) * 1995-12-01 1997-06-05 Eli Lilly And Company Stable vancomycin hydrochloride solutions
JPH1180021A (ja) 1997-09-02 1999-03-23 Kayaku:Kk バンコマイシン注射剤
KR100856479B1 (ko) * 2000-05-02 2008-09-04 세라밴스 인코포레이티드 환원성 알킬화 방법
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
ES2316445T3 (es) * 2000-05-02 2009-04-16 Theravance, Inc. Composicion que contiene una ciclodextrina y un antibiotico glicopeptidico.
CA2413251C (en) * 2000-06-21 2012-06-12 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
JP2007523887A (ja) * 2003-10-31 2007-08-23 ザ・ユニヴァーシティ・オブ・カンザス スルホアルキルエーテル−アルキルエーテルシクロデキストリン誘導体
ES2482700T3 (es) 2005-02-14 2014-08-04 Venus Remedies Limited Terapia de combinación parenteral para enfermedades infecciosas causadas por una bacteria resistente a los medicamentos
CN1857716A (zh) * 2006-03-14 2006-11-08 浙江大学 注射用盐酸万古霉素及其制备方法
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
CA2699550C (en) 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102755629A (zh) * 2012-08-02 2012-10-31 上海瑞创医药科技有限公司 与万古霉素形成抗菌增效包合物的组分和制备方法及其应用
ES2743039T3 (es) * 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US9616098B2 (en) 2013-05-30 2017-04-11 Scidose, Llc Formulations of vancomycin
SI3542812T1 (sl) * 2014-11-06 2021-04-30 Xellia Pharmaceuticals Aps Glikopeptidni sestavki
EA036750B1 (ru) 2016-01-08 2020-12-16 Гуфик Байосайенсиз Лимитед Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления
KR20180111948A (ko) * 2016-02-18 2018-10-11 멜린타 테라퓨틱스, 인크. 오리타반신 제제

Similar Documents

Publication Publication Date Title
JP2019518733A5 (enExample)
JP2017533218A5 (enExample)
HRP20210342T1 (hr) Pripravci glikopeptida
CY1123242T1 (el) Λυοφιλοποιημενο παρασκευασμα κυτταροτοξικων διπεπτιδιων
US9522966B2 (en) Hyaluronic acid derivative, method of preparation thereof, method of modification thereof and use thereof
WO2018156617A3 (en) Compositions and methods for delivery of polymer / biomacromolecule conjugates
WO2014120837A3 (en) Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
CY1118243T1 (el) Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα
BR112015023168A2 (pt) composições de dicetopiperazina microcristalina e métodos
BR112014014599A8 (pt) polímeros de alfa-aminoamidina e uso dos mesmos
MX353900B (es) Lipidoides de aminoalcohol y usos de los mismos.
AU2019376660A8 (en) 2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities
CN108178780B (zh) 一种短肽修饰单宁酸纳米抗菌剂及其制备方法
PH12021500011A1 (en) Anti-cd137 antigen-binding molecule and utilization thereof
WO2019090148A3 (en) Compositions and methods related to therapeutic cell systems for tumor growth inhibition
PL3927312T3 (pl) Minimalizacja aglomeracji, napowietrzania i konserwacji powłoki kompozycji farmaceutycznych zawierających Ibuprofen
WO2017141204A3 (en) Biguanide grafted / modified biopolymers as drug delivery vehicles
RU2015140720A (ru) Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой
RU2019109719A (ru) Конъюгаты полимиксин-альгинатных олигомеров
WO2015173427A4 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
Lin et al. Antimicrobial peptide-inspired antibacterial polymeric materials for biosafety
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
JP2014530882A5 (enExample)
JP2018536645A5 (enExample)
BR112017013269A2 (pt) ?composição farmacêutica líquida?